Business Description
Theravance Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : KYG8807B1068
Total Employee Number:
90Compare
Compare
Traded in other countries / regions
TBPH.USA0TB.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2014-05-16Description
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.74 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | 0.29 | |||||
Interest Coverage | 2.74 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.52 | |||||
Beneish M-Score | -5.13 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 44 | |||||
3-Year Book Growth Rate | -5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -6.09 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.31 | |||||
9-Day RSI | 59.15 | |||||
14-Day RSI | 55.01 | |||||
3-1 Month Momentum % | -0.06 | |||||
6-1 Month Momentum % | -16.94 | |||||
12-1 Month Momentum % | 51.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.14 | |||||
Quick Ratio | 13.14 | |||||
Cash Ratio | 12.42 | |||||
Days Sales Outstanding | 77.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 7.8 | |||||
Shareholder Yield % | 1.46 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 4.54 | |||||
Net Margin % | 104.34 | |||||
EBITDA Margin % | 128.74 | |||||
FCF Margin % | 244.85 | |||||
OCF Margin % | 244.85 | |||||
ROE % | 47.3 | |||||
ROA % | 26.72 | |||||
ROIC % | 3.76 | |||||
3-Year ROIIC % | -64.64 | |||||
ROC (Joel Greenblatt) % | 373.35 | |||||
ROCE % | 35.58 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 7.7 | |||||
Forward PE Ratio | 6.51 | |||||
PE Ratio without NRI | 15.91 | |||||
Price-to-Owner-Earnings | 3.52 | |||||
PS Ratio | 8.02 | |||||
PB Ratio | 3 | |||||
Price-to-Tangible-Book | 3 | |||||
Price-to-Free-Cash-Flow | 3.2 | |||||
Price-to-Operating-Cash-Flow | 3.2 | |||||
EV-to-EBIT | 3.77 | |||||
EV-to-EBITDA | 3.7 | |||||
EV-to-Revenue | 4.77 | |||||
EV-to-Forward-Revenue | 2.84 | |||||
EV-to-FCF | 1.95 | |||||
Price-to-GF-Value | 0.9 | |||||
Price-to-Median-PS-Value | 0.54 | |||||
Price-to-Graham-Number | 1.46 | |||||
| Price-to-Net-Current-Asset-Value | 3.7 | |||||
| Price-to-Net-Cash | 4.1 | |||||
Earnings Yield (Greenblatt) % | 26.53 | |||||
FCF Yield % | 30.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TBPH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Theravance Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 109.775 | ||
| EPS (TTM) ($) | 2.2 | ||
| Beta | 0.633 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 1.06 | ||
| Volatility % | 48.34 | ||
| 14-Day RSI | 55.01 | ||
| 14-Day ATR ($) | 0.109726 | ||
| 20-Day SMA ($) | 16.88225 | ||
| 12-1 Month Momentum % | 51.74 | ||
| 52-Week Range ($) | 11.2 - 21.03 | ||
| Shares Outstanding (Mil) | 51.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Theravance Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Theravance Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 17:00 | In 95 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 94 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 17:00 | In 5 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 4 days | ||
| General meeting for 2026 | 2026-06-12 | 16.49 (+0.12%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 16.94 (+0.95%) | ||
| Annual report for 2025 | 2026-03-23 | 14.33 (+1.85%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 08:30 | 13.83 (-0.43%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-04 08:20 | 18.89 (+0.75%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-10 17:00 | 14.75 (-0.81%) |
Show
Entries
Theravance Biopharma Inc Frequently Asked Questions
What is Theravance Biopharma Inc(TBPH)'s stock price today?
The current price of TBPH is $16.93. The 52 week high of TBPH is $21.03 and 52 week low is $11.20.
When is next earnings date of Theravance Biopharma Inc(TBPH)?
The next earnings date of Theravance Biopharma Inc(TBPH) is 2026-08-12 Est..
Does Theravance Biopharma Inc(TBPH) pay dividends? If so, how much?
Theravance Biopharma Inc(TBPH) does not pay dividend.
Guru Commentaries on NAS:TBPH
No articles.
Press Release
Articles on Theravance Biopharma Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers